Tenderwize
Back to tender search

Non-exclusive Drug Discount Agreement for Cinnarizin/Dimenhydrinat

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Apr 30, 2027 · 251 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Cinnarizin/Dimenhydrinat (ATC-Code nach WHO: N07CA52; amtlicher ATC: N07CA22)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

40 / 100

Complexity

30 / 100

Risk factors

No guaranteed quantities; actual demand depends on patient numbers, prescription behavior, and pharmacy stocking. Reven...

AOK PLUS may terminate the Open-House procedure if exclusive agreements are signed, typically 8-12 months after notice...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Supply of pharmaceutical products containing Cinnarizin/Dimenhydrinat (ATC N07CA52/N07CA22) under non-exclusive discount agreements.
  • Participation via Open-House model; no negotiations.
Show full summary

Non-exclusive drug discount agreement (Rabattvereinbarung) under §130a Abs.8 SGB V for Cinnarizin/Dimenhydrinat (ATC N07CA52/N07CA22) via an Open-House model. Issued by AOK PLUS for Saxony and Thuringia. No guaranteed volumes or exclusivity. Multiple submission deadlines; first deadline 2025-05-05. Contract runs until 30.04.2027. Open to all pharmaceutical undertakings meeting requirements. No estimated value provided. Award criteria not specified. Selection criteria: self-declaration of no exclusion grounds (GWB) and Russia sanctions compliance.

Risks

No guaranteed quantities; actual demand depends on patient numbers, prescription behavior, and pharmacy stocking. Reven...

AOK PLUS may terminate the Open-House procedure if exclusive agreements are signed, typically 8-12 months after notice...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical undertaking as defined in §4 Abs.18 AMG.

Eligibility

  • Must submit self-declaration of no exclusion grounds (§§123,124 GWB).

Administrative

  • Must submit self-declaration regarding EU Russia sanctions (Art.5k Regulation 833/2014).

Requirements may be incomplete.

Buyer

Location

Erfurt, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Cinnarizin/Dimenhydrinat

Open-House model for concluding non-exclusive discount agreements for the active substance Cinnarizin/Dimenhydrinat. No guaranteed minimum quantities, no exclusivity. Contract end date 30.04.2027. Place of performance: Dresden, Saxony/Thuringia, Germany.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

May 2025 - Apr 2027

Category

Pharmaceutical products

Deadline

Deadline Apr 30, 2027

Procurement Details

Publication date
24 Mar 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
190844-2025

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3